<DOC>
	<DOCNO>NCT02108444</DOCNO>
	<brief_summary>This study retrospective analysis explore incidence hepatitis B virus reactivation withdrawal prophylactic antiviral therapy , efficacy safety chemotherapy , overall survival rate lymphoma patient hepatitis B virus infection .</brief_summary>
	<brief_title>Hepatitis B Virus Reactivation After Withdrawal Prophylactic Antiviral Therapy Lymphoma Patients</brief_title>
	<detailed_description>All eligible patient receive prophylactic antiviral therapy within 6 month chemotherapy previous sudy . We assign specific intervention subject study . The primary endpoint study incidence hepatitis B virus reactivation withdrawal prophylactic antiviral therapy . The secondary endpoint include incidence hepatitis flare relate hepatitis B virus reactivation withdrawal prophylactic antiviral therapy , tumor response rate , overall survival rate .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>treatmentnaive patient lymphoma patient history previous exposure hepatitis B virus ( HBV ) : HBsAg hepatitis B core antibody ( antiHBc ) positive HBsAg HBcAb negative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>hepatitis</keyword>
	<keyword>hepatitis B</keyword>
	<keyword>lymphoma</keyword>
	<keyword>Hematologic Diseases</keyword>
</DOC>